Skip to main content

Risk for Second Primary Breast Cancer Low in Certain Young Breast Cancer Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on April 16, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 16, 2024 -- Young breast cancer (BC) survivors (40 years or younger) without a pathogenic variant (PV) have a low risk for developing second primary BC (SPBC), according to a study published online April 11 in JAMA Oncology.

Kristen D. Brantley, Ph.D., M.P.H., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues estimated the cumulative incidence of SPBC in women diagnosed with BC at or younger than age 40 years. Participants were enrolled in a prospective study including 1,297 women diagnosed with stage 0 to III BC.

The analyses included 685 women with stage 0 to III BC who underwent unilateral mastectomy or lumpectomy. The researchers found that 2.5 percent of patients developed an SPBC during a median follow-up of 10.0 years; two of these 17 patients had cancer in the ipsilateral breast after lumpectomy. There was a median of 4.2 years from primary BC diagnosis to SPBC. The 10-year risk for SPBC was 2.2 and 8.9 percent among women who did not carry a PV and for carriers of a PV, respectively, among 577 women who underwent genetic testing. The risk for SPBC was higher among PV carriers versus noncarriers in multivariate analyses (subdistribution hazard ratio, 5.27; 95 percent confidence interval, 1.43 to 19.43) and for women with primary in situ versus invasive BC (subdistribution hazard ratio, 5.61; 95 percent confidence interval, 1.52 to 20.70).

"The results of this cohort study suggest a relatively low five- and 10-year cumulative incidence of SPBC among patients aged 40 years or younger with BC who are noncarriers of PVs, emphasizing the importance of genetic testing among patients with BC," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States

THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...

Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...

Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening

WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.